GermanyGermany

Finalists of the European Biotechnica Award nominated

26.08.2009

Hanover - The jury of the European Biotechnica Award has selected the three finalists for 2009: The nominees are the biopharmaceutical companies NovImmune, Switzerland, TRION Pharma GmbH, Germany, and Vivalis, France. The award recognizes the achievements of young, innovative European companies from the areas of biotechnology and the life sciences.
NovImmune develops monoclonal antibodies for the treatment of inflammatory and immune-related disorders. The company is based in Plan-les-Quates, near Geneva, Switzerland, and so far has generated seven monoclonal antibodies with the intent to treat immune-related disorders.
TRION Pharma is a biopharmaceutical company that develops trifunctional antibodies called Triomab® at its site in Munich. They are based on a platform technology for which TRION Pharma holds IP rights around the world. Triomab® antibodies simultaneously activate multiple immune defence mechanisms against cancer.
Vivalis provides the pharmaceutical industry with cell-based solutions for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. Headquartered in France, the company specialises in the field of embryonic stem cells and their practical applications in human and veterinary medicine.
The international jury of experts, consisting of eleven members and chaired by Prof. Dr. Peter Stadler, CEO of Artemis Pharmaceuticals in Cologne, will decide on the ultimate winner immediately before the award ceremony during the BIOTECHNICA opening event on 5 October. The winner will receive prize money of EUR 30,000. In addition, all finalists will receive numerous non-cash prizes. The award will be presented by opening speakers Janez Potocnik, EU Commissioner for Science and Research, Dr. Philipp Rösler; Minister of Economics, Lower Saxony; Dr. Stefan Marcinowski, Member of the Board of Executive Directors of BASF and President of the German Association of Biotechnology Industries; and Kary Mullis, winner of the Nobel Prize in Chemistry.

GermanyGermany

07.03.2012

The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...

GermanyGermany

07.03.2012

Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...

GermanyGermany

05.03.2012

Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...

GermanyGermany

05.03.2012

German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....

GermanyGermany

29.02.2012

Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight. The 2011 total revenue was...

GermanyGermany

17.02.2012

Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...

27.01.2012

Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...

GermanyGermany

20.01.2012

Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...

GermanyGermany

17.01.2012

Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...

GermanyGermany

10.01.2012

Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-germany/article/finalists-of-the-european-biotechnica-award-nominated.html

Image Gallery

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)344.00 GBP12.6%
  • THERAMETRICS (CH)0.11 CHF10.0%
  • ACTIVE BIOTECH (S)35.60 SEK9.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • BAVARIAN NORDIC (D)13.63 EUR-6.4%

TOP

  • BIOTECH PHARMACON (N)19.00 NOK73.5%
  • WILEX (D)0.81 EUR42.1%
  • E-THERAPEUTICS (UK)28.00 GBP40.0%

FLOP

  • CYTOS (CH)0.16 CHF-94.1%
  • BIONOR PHARMA (N)2.17 NOK-45.7%
  • IMMUNICUM AB (S)16.40 SEK-36.9%

TOP

  • SILENCE THERAPEUTICS (UK)257.25 GBP6174.4%
  • IXICO (UK)66.50 GBP737.5%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.16 CHF-96.1%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper